Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 9/20 | 0.54 |
| ▸ | CCNA1 | P78396 | 9/20 | 0.54 |
| ▸ | IKBKB | O14920 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 7/20 | 0.42 |
| ▸ | CA2 | P00918 | 7/20 | 0.42 |
| ▸ | CA9 | Q16790 | 7/20 | 0.42 |
| ▸ | CA4 | P22748 | 6/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5226367 | 0.90 | CCNA2 (0.55) | CDK2CCNA2CCNA1IKBKBPTGS2 | |
| SCHEMBL5226285 | 0.88 | CCNA2 (0.58) | CDK2CCNA2CCNA1IKBKBPTGS2 | |
| SCHEMBL5230251 | 0.87 | CDK2 (0.44) | CDK2CCNA2CCNA1IKBKBPTGS2 | |
| SCHEMBL5225835 | 0.87 | CCNA2 (0.57) | CDK2CCNA2CCNA1IKBKBPTGS2 | |
| SCHEMBL5227808 | 0.85 | CCNA2 (0.43) | CDK2CCNA2CCNA1IKBKBCA1 | |
| SCHEMBL5230469 | 0.85 | CDK2 (0.52) | CDK2CCNA2CCNA1IKBKBPTGS2 | |
| SCHEMBL5225569 | 0.85 | CCNA2 (0.52) | CDK2CCNA2CCNA1IKBKB | |
| SCHEMBL5230705 | 0.85 | CDK2 (0.52) | CDK2CCNA2CCNA1IKBKB | |
| SCHEMBL5229177 | 0.84 | CCNA2 (0.50) | CDK2CCNA2CCNA1 | |
| SCHEMBL5230050 | 0.84 | CCNA2 (0.42) | CDK2CCNA2CCNA1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478357-B1 | TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-01-31 | — | — | EP | claimed |
| US-20050176796-A1 | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents | PHARMACIA ITALIA S.P.A. (IT) | 2005-08-11 | — | — | US | claimed |
| US-20240034799-A1 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | CEDARS SINAI MEDICAL CENTER (US) | 2024-02-01 | — | — | US | disclosed |
| EP-4256086-A1 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | Cedars-Sinai Medical Center (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230279491-A1 | TREATMENTS FOR A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS | CEDARS-SINAI MEDICAL CENTER | 2023-09-07 | — | — | US | disclosed |
| WO-2022119842-A1 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | CEDARS-SINAI MEDICAL CENTER (US) | 2022-06-09 | — | — | WO | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-7970581-B2 | Methods of calculating differences of binding affinities between congeneric pairs of ligands by way of a displaced solvent functional | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-06-28 | — | — | US | disclosed |
| US-7970581-B2 | Methods of calculating differences of binding affinities between congeneric pairs of ligands by way of a displaced solvent functional | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-06-28 | — | — | US | disclosed |
| US-7970580-B2 | Methods of calculating differences of binding affinities between congeneric pairs of ligands by way of a displaced solvent functional | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-06-28 | — | — | US | disclosed |
| US-7970580-B2 | Methods of calculating differences of binding affinities between congeneric pairs of ligands by way of a displaced solvent functional | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100241411-A1 | Methods of Calculating Differences of Binding Affinities Between Congeneric Pairs of Ligands by Way of a Displaced Solvent Functional | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-09-23 | — | — | US | disclosed |
| US-20100241411-A1 | Methods of Calculating Differences of Binding Affinities Between Congeneric Pairs of Ligands by Way of a Displaced Solvent Functional | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-09-23 | — | — | US | disclosed |
| US-20100241412-A1 | Methods of Calculating Differences of Binding Affinities Between Congeneric Pairs of Ligands by Way of a Displaced Solvent Functional | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-09-23 | — | — | US | disclosed |
| US-20100241412-A1 | Methods of Calculating Differences of Binding Affinities Between Congeneric Pairs of Ligands by Way of a Displaced Solvent Functional | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-09-23 | — | — | US | disclosed |
| US-7756674-B2 | Methods of calculating differences of binding affinities between congeneric pairs of ligands by way of a displaced solvent functional | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090037136-A1 | Methods of calculating differences of binding affinities between congeneric pairs of ligands by way of a displaced solvent functional | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-05 | — | — | US | disclosed |
| EP-1478357-B1 | TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-01-31 | — | — | EP | disclosed |
| US-20050176796-A1 | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents | PHARMACIA ITALIA S.P.A. (IT) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176796-A1 | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents | TP53, NFATC1, MAP3K15 | CDK2 178/4885CCNA2 1338/4885CCNA1 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.